Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Total Non-Current Liabilities (2020 - 2025)

P3 Health Partners (PIII) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $682.1 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Total Non-Current Liabilities fell 5.39% year-over-year to $682.1 million, compared with a TTM value of $682.1 million through Jun 2025, down 5.39%, and an annual FY2024 reading of $623.6 million, changed N/A over the prior year.
  • Total Non-Current Liabilities was $682.1 million for Q2 2025 at P3 Health Partners, up from $623.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $865.2 million in Q1 2023 and bottomed at $186382.0 in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $414.1 million, with a median of $375.3 million recorded in 2023.
  • Peak annual rise in Total Non-Current Liabilities hit 53381.0% in 2022, while the deepest fall reached 30.92% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $390352.0 in 2021, then surged by 89336.71% to $349.1 million in 2022, then skyrocketed by 102.54% to $707.1 million in 2023, then fell by 11.81% to $623.6 million in 2024, then rose by 9.39% to $682.1 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for PIII at $682.1 million in Q2 2025, $623.6 million in Q4 2024, and $712.8 million in Q3 2024.